Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CVM vs ANRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: CVM 1 – 4 ANRO (1 Tie) Matrix Metrics: CVM 3 – 5 ANRO

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -62.7% YoY).
  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile ANRO is in a Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs ANRO
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.91
+14.76% 1D
Market Cap $22.5M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.45β · 139% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 61.8 · SMA20: $1.48 · SMA50: $1.67
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.12
-7.37% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.03β · 94% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.0 · SMA20: $24.87 · SMA50: $25.98

6-Pillar Scorecard Institutional Category Breakdown (CVM 1 – 4 ANRO)

Columns: Metric · CVM · ANRO
1. Valuation Multiples CVM
Forward P/E 23.0x N/M
Trailing P/E 23.0x N/M
PEG Ratio 1.12x N/M
EV / Revenue N/M N/M
2. Growth & Scale ANRO
Revenue Growth (YoY) -62.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28,558 N/A
Market Cap $22.5M $1.2B
3. Profitability & Quality ANRO
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -252.5% -46.7%
4. Balance Sheet & Cash Flow ANRO
Cash Generation (TTM) -$17M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $301M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANRO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 79.4% (8th %ile)
Put/Call OI Skew N/A 0.04x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (3) vs ANRO (5)
Institutional Metric CVM ANRO Criterion Row Edge
Market Capitalization
Scale
$22.5M $1.2B Larger Scale ANRO
Trailing P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Forward P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Revenue Growth (YoY)
Growth
-62.7% +0.0% Higher Growth ANRO
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-252.5% -46.7% Higher ROE ANRO
52-Week Range Position
Momentum
15% ($1–$8) 54% ($11–$37) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
0.45β · 139% Vol 2.03β · 94% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$28,558 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) -$80M ($301M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVM +5.37 pp
CVM: +15.45% · ANRO: +10.08%
3M Horizon CVM +44.16 pp
CVM: +16.16% · ANRO: -28.0%
6M Horizon ANRO +3.03 pp
CVM: +19.81% · ANRO: +22.84%
1Y Horizon ANRO +178.65 pp
CVM: -71.22% · ANRO: +107.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CVM vs ANRO. Trailing 12-month operating profitability (CVM 0.0% vs ANRO 0.0%) and valuation multiples (CVM 23.0x vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CVM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28,558
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-252.5% · 23.0x
ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $22.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs ANRO Key Questions & Quantitative Answers

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -62.7% YoY). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile ANRO is in a Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CVM generates $28,558 in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.

CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus ANRO (-46.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.45β · 139% Vol realized risk). By comparison, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.03β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.